Factors affecting performance and thromboembolism after porcine xenograft cardiac valve replacement.
Long-term durability and the need for anticoagulation in conjunction with the use of porcine valves remain questionable. We analyzed valve dysfunction and thromboembolism in 325 adult (older than 20 years) and 31 pediatric survivors who received 407 porcine xenograft valves from June, 1974, to September, 1980 (46% of all valve replacements). Valves at risk in the adults were 216 aortic, 138 mitral, and 22 tricuspid; in children, 14 aortic, eight mitral, seven pulmonary, and two tricuspid. Mean follow-up was 38 (9 to 85) months. Twenty-seven valved conduits also were followed up for 9 to 85 (mean 52) months. Two late deaths in children resulted from dysfunction and another from endocarditis. One late death in an adult was caused by embolism. The other 36 deaths in the entire group were not valve related. Dysfunction requiring reoperation at 12 to 37 months occurred in eight of 325 adults (six mitral, one aortic, and one tricuspid). Dysfunction was due to recurrent endocarditis in six and to primary tissue failure in two (both older than 35 years of age); all survived reoperation. However, in children, severe dysfunction due to primary tissue failure occurred in seven (23%) cardiac valves, necessitating replacement at 21 to 48 months, and three of 27 conduits had to be replaced at 39 to 70 months. Thromboembolism occurred in six adults with mitral xenografts but none with aortic or tricuspid valve. Four of the patients with thromboemboli (one of whom died) were among 16 who had atrial fibrillation and no warfarin, but aspirin and persantine (11.7%/patient-year) and two were among 14 with sinus rhythm on no medication. No thromboembolism occurred in patients with mitral xenografts who were in sinus rhythm and receiving antiplatelet agents or in those with atrial fibrillation receiving warfarin. This experience indicates a high incidence of relatively early failure of porcine xenograft cardiac valves in children and young adults but excellent medium and long-term performance in older adults, in whom severe dysfunction occurred mainly with recurrent endocarditis. Thromboembolism occurred primarily in patients with mitral replacement especially with atrial fibrillation and no anticoagulants.
D000328:Adult; D000368:Aged; D000818:Animals; D001705:Bioprosthesis / Q000009:adverse effects*; D002648:Child; D004437:Ebstein Anomaly / Q000601:surgery; D004696:Endocarditis / Q000601:surgery; D005500:Follow-Up Studies; D006349:Heart Valve Diseases / Q000601:surgery; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D013552:Swine; D013923:Thromboembolism / Q000209:etiology*